Results 171 to 180 of about 74,688 (254)

Comparative efficacy of Palbociclib and Everolimus with aromatase inhibitors in second line treatment of HR and HER2 negative metastatic breast cancer. [PDF]

Discov Oncol
Najafizade N, Zarei S, Elhaie M, Roayaei M.   +3 more
europepmc   +1 more source

Data from A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors

, 2023
Chester E. Chamberlain, Michael S. German, Katherine S. Yang, Jason Wang, Henry F. VanBrocklin, Melanie Regan, Kevan M. Shokat, Gregory S. Ducker, Grace Kim, Byron Hann, David B. Donner, Robert S. Warren, Alan P. Venook, Emily K. Bergsland, Danny Lee, Yucheng Wang, Eric K. Nakakura   +16 more
openalex   +1 more source

Pharmacokinetics and safety of the antitumor drug everolimus in healthy Chinese subjects: a single-dose, open-label, randomized, two-sequence, two-period crossover, phase I bioequivalence study. [PDF]

Front Pharmacol
Chen X, Yi X, Liu Y, Wang X, Peng Y, Wang Q, Shuai Y, Zhang H.   +7 more
europepmc   +1 more source

Cardiovascular Events with De Novo Use of Everolimus in Heart Transplant Recipients: 24-Month Analysis of the A2310 Study [PDF]

, 2013
Luciano Potena, Ulrik Pagh Schultz, Christoph Bara, José M. Arizón, Gaohong Dong, Patricia López, Éric Epailly   +6 more
openalex   +1 more source

Impact of neuroendocrine neoplasm-specific systemic treatments on expression and function of CXCR4 in neuroendocrine tumor cells. [PDF]

Sci Rep
Däubler C, Böttcher C, Landwehr LS, Meining A, Michalski K, Reiter F, Werner RA, Hartrampf P, Rogoll D, Weich A.   +9 more
europepmc   +1 more source

Supplementary Figure S2 from SAR-096: Phase II Clinical Trial of Ribociclib in Combination with Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)

Sujana Movva, Sahar Matloob, Elizabeth A. Handorf, Edwin Choy, Priscilla Merriam, Douglas B. Flieder, Kathy Q. Cai, Yan Zhou, Eric D. Tetzlaff, Cheyenne Pagan, Emma Barker, Rosanna Veggeberg, Delia Zumpano, Lori Rink, Margaret von Mehren, Suzanne George   +15 more
openalex   +1 more source

Effectiveness and Safety of Lenvatinib and Everolimus after Immune Checkpoint Inhibitors in Metastatic Renal Cell Cancer: A Systematic Review. [PDF]

Oncol Res
Iovane G, Traman L, Maffezzoli M, Fornarini G, Corradi D, Guareschi D, Santoni M, Buti S.   +7 more
europepmc   +1 more source

Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study

, 2018
William P. Tew, Michael W. Sill, Joan L. Walker, Angeles Alvarez Secord, Albert J. Bonebrake, Jeanne M. Schilder, Ashley Stuckey, Laurel W. Rice, Krishnansu S. Tewari, Carol Aghajanian   +9 more
openalex   +2 more sources

Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial. [PDF]

ESMO Open
Capdevila J, Tafuto S, Krogh M, Teulé A, Garcia-Carbonero R, Klümpen HJ, Cremer B, Sevilla I, Eriksson B, Tabaksblat E, Metges JP, Reed NS, Schrader J, Navarro V, Valentí V, Hernando J, Colao AM, Vestermark L, Carnaghi C, Knigge UP, Jimenez-Fonseca P, Benavent M, de Vos-Geelen J, Venerito M, Von Werder A, Jann H, Rinke A, Smith D, Hörsch D, Starling N, Ruszniewski P, Baudin E, Caroli-Bosc FX, Manzano JL, Martín M, Scarpa A, Lawlor RT, Ragulan C, Ps H, Sadanandam A, Carmona-Bayonas A, Salazar R.   +41 more
europepmc   +1 more source

Differential Effects of Everolimus and Cyclosporine A on Intimal ?????Actin-Positive Cell Dynamics of Carotid Allografts in Mice

, 2004
Yuji Matsumoto, Akiko Hof, Yves Baumlin, Matthias M ller, Robert P. Hof   +4 more
openalex   +2 more sources